188 related articles for article (PubMed ID: 1348583)
1. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia.
Friedman L; Jesberger JA; Meltzer HY
Psychiatry Res; 1992 Jan; 41(1):25-36. PubMed ID: 1348583
[TBL] [Abstract][Full Text] [Related]
2. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia.
Litman RE; Hommer DW; Radant A; Clem T; Pickar D
Schizophr Res; 1994 May; 12(2):107-20. PubMed ID: 8043521
[TBL] [Abstract][Full Text] [Related]
3. Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.
Lencer R; Sprenger A; Harris MS; Reilly JL; Keshavan MS; Sweeney JA
Arch Gen Psychiatry; 2008 Oct; 65(10):1146-54. PubMed ID: 18838631
[TBL] [Abstract][Full Text] [Related]
4. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
[TBL] [Abstract][Full Text] [Related]
5. Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings.
Friedman L; Jesberger JA; Siever LJ; Thompson P; Mohs R; Meltzer HY
Psychol Med; 1995 Mar; 25(2):387-403. PubMed ID: 7675926
[TBL] [Abstract][Full Text] [Related]
6. Smooth pursuit and saccadic abnormalities in first-episode schizophrenia.
Hutton SB; Crawford TJ; Puri BK; Duncan LJ; Chapman M; Kennard C; Barnes TR; Joyce EM
Psychol Med; 1998 May; 28(3):685-92. PubMed ID: 9626724
[TBL] [Abstract][Full Text] [Related]
7. The effect of change in clinical state on eye movement dysfunction in schizophrenia.
Kallimani D; Theleritis C; Evdokimidis I; Stefanis NC; Chatzimanolis I; Smyrnis N
Eur Psychiatry; 2009 Jan; 24(1):17-26. PubMed ID: 18922684
[TBL] [Abstract][Full Text] [Related]
8. Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report.
Rosenberg PB; Rosse RB; Johri SK; Kendrick K; Fay-McCarthy M; Collins JP; Tsui LC; Wyatt RJ; Deutsch SI
Clin Neuropharmacol; 1996 Jun; 19(3):276-81. PubMed ID: 8726548
[TBL] [Abstract][Full Text] [Related]
9. A quantitative analysis of saccades and smooth pursuit during visual pursuit tracking. A comparison of schizophrenics with normals and substance abusing controls.
Radant AD; Hommer DW
Schizophr Res; 1992 Mar; 6(3):225-35. PubMed ID: 1349241
[TBL] [Abstract][Full Text] [Related]
10. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders.
de Haan L; Linszen DH; Gorsira R
J Clin Psychiatry; 1999 Jun; 60(6):364-5. PubMed ID: 10401913
[TBL] [Abstract][Full Text] [Related]
11. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients.
Sajatovic M; Ramirez LF; Kenny JT; Meltzer HY
Compr Psychiatry; 1994; 35(1):29-33. PubMed ID: 8149726
[TBL] [Abstract][Full Text] [Related]
12. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.
Friedman JH
Mov Disord; 1994 May; 9(3):321-4. PubMed ID: 7913739
[TBL] [Abstract][Full Text] [Related]
13. [Eye tracking disorders in schizophrenic patients and their parents].
Boudet C; Denise P; Bocca ML; Chabot B; Abadie P; Brazo P; Benali K; Dollfus S
Encephale; 2001; 27(6):551-8. PubMed ID: 11865562
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
15. Smooth pursuit eye movements in schizophrenia: influences of neuroleptic treatment and the question of specificity.
Küfferle B; Friedmann A; Topitz A; Földes P; Anderer P; Kutzer M; Steinberger K
Psychopathology; 1990; 23(2):106-14. PubMed ID: 1979684
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study.
Nyakyoma K; Morriss R
Psychopharmacol Bull; 2010; 43(2):67-81. PubMed ID: 21052043
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
[TBL] [Abstract][Full Text] [Related]
19. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
20. Effects of stringent criteria on eligibility for clozapine among public mental health clients.
Juarez-Reyes MG; Shumway M; Battle C; Bacchetti P; Hansen MS; Hargreaves WA
Psychiatr Serv; 1995 Aug; 46(8):801-6. PubMed ID: 7583481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
